Condition: Neovascular Age-related Macular Degeneration (nAMD) · Sponsor: EyebioKorea, Inc.
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients with neovascular Age-related Macular Degeneration (nAMD), and to secondarily evaluate the clinical efficacy. Subject to Adults aged 50 years or older and Neovascular age-related macular degeneration (nAMD)
This description comes directly from the study's public registry record.
SUYEON KIM · 1047070314 · suyeon@eyebiokorea.com
YUNSEOK CHO · 70-4129-7497 · yscho@eyebiokorea.com
Always discuss trial participation with your own doctor first.
| Busan Paik Hospital, Inje University | Busan, South Korea | Recruiting |
| Pusan National University Hospital | Busan, South Korea | Recruiting |
| Yeungnam University Medical Center | Daegu, South Korea | Recruiting |
| Kim's Eye Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06487039